First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of pomalidomide and bortezomib when
given together with dexamethasone in treating patients with amyloid light-chain amyloidosis
or light chain deposition disease. Biological therapies, such as pomalidomide, may stimulate
the immune system in different ways and stop abnormal cells from growing. Bortezomib may stop
the growth of abnormal cells by blocking some of the enzymes needed for cell growth. Giving
pomalidomide and bortezomib together with dexamethasone may be an effective treatment for
amyloid light-chain amyloidosis or light chain deposition disease